Clinical Trials
The expanded deal builds on a previous agreement signed in June 2021, under which Innovent is granted to deploy Synaffix's ADC technologies on a targe...
December 07, 2023 | News
The partnership gives sponsors easier access to a wider pool of participants by driving awareness about trials to Chemist Warehouse's customers in Australi...
December 06, 2023 | News
Cohort 1 is comprised of eight subjects who completed dosing and were followed over a period of 140 days. Safety data showed there were no dose-limiting to...
December 06, 2023 | News
Lycia is using its proprietary lysosomal targeting chimeras (LYTACs) platform to discover and develop first-in-class therapeutics that degrade extracellula...
December 05, 2023 | News
ISM5411 is an oral, PHD-specific inhibitor that facilitates the treatment of IBD by inducing the expression of gut barrier protective genes. ISM5411 is ...
December 05, 2023 | News
Clarivate Plc (NYSE:CLVT), a global leader in connecting people and organizations to intelligence they can trust to transform their world, ...
December 05, 2023 | News
ALINA is the first and only Phase III study to show an improvement in disease-free survival in patients from Asia with early-stage resected ALK-posit...
December 04, 2023 | News
At AWS re:Invent, Amazon Web Services, Inc. (AWS), an Amazon.com, Inc. company (NASDAQ: AMZN), today announced it is working with Accenture (NYSE: ACN...
November 30, 2023 | News
Cohort 3 of the theranostic SECuRE trial investigating 64Cu/67Cu-SAR-bisPSMA in metastatic castrate-resistant prostate cancer (mCRPC) has enrolled a...
November 30, 2023 | News
Updates are supported by data from the Phase 1/2 EPCORE™ NHL-1 clinical trial AbbVie announced updates from the U...
November 29, 2023 | News
--Nefecon® is the first approved medicine with an IgAN indication in China-- --The approval marks a new era of IgAN treatment for Chinese patient...
November 27, 2023 | News
Final stage in licensing OVM-200 from Oxford Vacmedix in the UK- DxVx plans to proceed its own clinical trials in Asia, including Korea and Chi...
November 27, 2023 | News
Pursuant to the Agreement, Simcere obtains the exclusive rights in the development, manufacturing, and commercialization of Rademikibart for all indication...
November 24, 2023 | News
“We are committed to developing novel molecules with the potential to transform the therapeutic landscape for cancer patients, and this partnership f...
November 23, 2023 | News
Most Read
Bio Jobs
News